object
previou
studi
pneumonia
outbreak
caus
novel
coronaviru
diseas
base
inform
gener
popul
howev
limit
data
avail
sever
acut
respiratori
syndrom
coronaviru
reactiv
studi
aim
evalu
clinic
characterist
reactiv
method
clinic
record
laboratori
result
chest
ct
scan
retrospect
review
patient
laboratoryconfirm
pneumonia
ie
throat
swab
sampl
posit
admit
novel
human
coronaviru
new
strain
rna
virus
recogn
wuhan
china
dec
novel
coronaviru
offici
name
sever
acut
respiratori
syndrom
intern
committe
taxonomi
virus
ictv
pneumonia
caus
recent
identifi
coronaviru
diseas
spread
quickli
across
hubei
provinc
region
china
also
global
alert
issu
world
health
organ
could
induc
symptom
includ
fever
dri
cough
dyspnea
fatigu
lymphopenia
patient
might
result
sever
acut
respiratori
syndrom
sar
even
death
sever
case
belong
betacoronaviru
lineag
phylogenet
tree
share
ident
sequenc
bat
sarslik
coronaviru
origin
sar
epidem
viru
current
remain
determin
origin
possibl
intermedi
anim
vector
well
mechan
viru
spread
among
human
despit
mani
report
character
clinic
epidemiolog
laboratori
radiolog
featur
well
treatment
clinic
outcom
patient
pneumonia
inform
reactiv
remain
report
cur
erad
therapi
current
avail
urgent
question
need
address
promptli
includ
whether
patient
pneumonia
reactiv
whether
risk
factor
predict
reactiv
patient
prevent
control
reactiv
retrospect
collect
analyz
detail
clinic
data
http
british
infect
associ
publish
elsevi
ltd
right
reserv
reactiv
patient
studi
present
clinic
featur
reactiv
patient
discuss
potenti
risk
factor
reactiv
retrospect
recruit
patient
diagnos
pneumonia
zhongnan
hospit
wuhan
univers
jan
feb
patient
compris
male
femal
median
age
rang
year
diagnosi
pneumonia
base
new
coronaviru
pneumonia
prevent
control
program
patient
pneumonia
test
posit
use
quantit
rtpcr
sampl
respiratori
tract
studi
review
approv
ethic
committe
zhongnan
hospit
wuhan
univers
written
inform
consent
waiv
ethic
commiss
emerg
infecti
diseas
review
clinic
record
laboratori
find
chest
ct
scan
patient
two
studi
investig
independ
review
data
throat
swab
sampl
collect
test
follow
guidelin
qrtpcr
statist
analysi
statist
analysi
done
spss
version
continu
variabl
directli
express
rang
categor
variabl
express
number
present
patient
histori
epidemiolog
exposur
patient
discharg
hospit
present
reactiv
age
rang
reactiv
patient
year
none
reactiv
patient
underli
diseas
diabet
chronic
hypertens
cardiovascular
diseas
one
patient
howev
histori
tuberculosi
mediastin
lymph
node
addit
reactiv
patient
exclud
influenza
viru
avian
influenza
viru
infect
upon
admiss
hospit
four
patient
present
fever
without
chill
one
high
fever
patient
bodi
temperatur
fluctuat
within
rang
one
patient
show
normal
bodi
temperatur
symptom
upper
respiratori
tract
infect
also
observ
one
patient
cough
one
sore
throat
patient
report
fatigu
tabl
addit
one
patient
show
constip
howev
none
patient
develop
sever
pneumonia
requir
mechan
ventil
die
pneumonia
feb
reactiv
patient
given
empir
antibiot
treatment
administ
antivir
therapi
tabl
data
laboratori
test
show
one
patient
progress
lymphopenia
cell
per
l
progress
elev
neutrophilia
cell
per
l
two
patient
elev
concentr
creactiv
protein
mgl
patient
normal
alanin
aminotransferas
alt
aspart
aminotransferas
ast
patient
chest
ct
scan
patient
show
typic
find
chest
ct
imagesmultipl
patchi
groundglass
shadow
lung
fig
confirm
significantli
proport
patient
reactiv
develop
discharg
hospit
report
clinic
data
patient
reactiv
clinic
characterist
patient
reactiv
similar
nonreactiv
patient
infect
none
patient
develop
sever
pneumonia
die
feb
notabl
base
find
patient
current
evid
suggest
proport
recov
patient
could
reactiv
reactiv
patient
includ
asymptomat
patient
symptomat
patient
suggest
reactiv
potenti
asymptomat
minim
symptomat
patient
time
neg
posit
rang
day
suggest
recov
patient
still
may
viru
carrier
requir
addit
round
viral
detect
isol
need
better
data
determin
risk
factor
mechan
caus
reactiv
time
onset
reactiv
variabl
depend
upon
host
factor
underli
diseas
type
immunosuppress
therapi
studi
recov
patient
posit
rtpcr
test
result
day
later
key
risk
factor
reactiv
would
includ
categori
host
statu
virolog
factor
type
degre
immunosuppress
host
factor
may
includ
sex
older
age
type
diseas
need
immunosuppress
although
could
identifi
risk
factor
host
factor
current
studi
potenti
requir
larg
cohort
confirm
virolog
factor
associ
increas
risk
reactiv
includ
high
baselin
load
variabl
genotyp
viral
load
would
also
link
treatment
respons
diseas
sever
progress
associ
genotyp
viral
load
reactiv
import
question
address
studi
patient
receiv
antivir
therapi
oseltamivir
arbidol
case
suggest
reactiv
may
occur
whatev
antivir
therapi
use
host
virolog
factor
import
consider
may
increas
likelihood
reactiv
therefor
assess
host
well
virolog
risk
factor
import
caveat
help
decid
whether
initi
prophylact
therapi
immunosuppress
immunosuppress
therapi
commonli
use
caus
agent
agent
gener
mechan
inhibit
mani
immun
function
exampl
steroid
inhibit
cellmedi
immun
suppress
interleukin
product
import
b
cell
prolifer
thu
surpris
gener
immunosuppress
effect
result
broad
immun
dysfunct
potenti
reactiv
reactiv
vex
persist
problem
consid
numer
patient
infect
previous
expos
viru
problem
pose
major
public
health
burden
term
global
morbid
possibl
mortal
current
find
reliabl
marker
predict
risk
reactiv
valid
test
determin
whether
particular
drug
therapi
associ
reactiv
latter
point
often
determin
empir
experi
although
decad
experi
help
us
identifi
import
drug
manag
situat
appropri
could
accur
evalu
risk
drug
prior
clinic
applic
consid
signific
ongo
global
public
health
emerg
although
conclus
limit
small
sampl
size
believ
find
import
understand
clinic
characterist
reactiv
potenti
patient
studi
support
part
grant
medic
scienc
advanc
program
clinic
medicin
wuhan
univers
funder
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
patient
provid
written
inform
consent
studi
procedur
perform
accord
ethic
standard
institut
ethic
review
committe
none
